Researchers implanted CRC tumors in mice to analyze how the Jagged 1 protein functioned. They found the Jagged 1 protein activates the Notch cell-signaling pathway, which inhibits cell differentiation.
Researchers discovered mice lack a fringe protein, which they said implied Jagged 1 is essential to activate Notch. Study director Dr. Lluís Espinosa said by inhibiting Jagged 1, tumor growth can be halted without affecting tissue growth.
Researchers treated the tumors without Notch with antibodies and found the tumors all shrunk and necrosed. Researchers intend to continue refining the treatment to attempt to make it patient-safe.
More articles on gastroenterology:
5 takeaways from ACG’s new Crohn’s disease recommendations
5 most-read GI/endoscopy stories: July 26-August 1
Entyvio drives Takeda’s Q1 revenue growth: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.